ID   HMV-II
AC   CVCL_1282
SY   HMV-2; HMVII; Human Melanoma Vagina-II
DR   BTO; BTO:0002918
DR   CLO; CLO_0003786
DR   CLO; CLO_0050086
DR   CLDB; cl1700
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-3610
DR   BCRJ; 0316
DR   BioSample; SAMN03472908
DR   cancercelllines; CVCL_1282
DR   Cell_Model_Passport; SIDM00291
DR   CGH-DB; 9289-4
DR   ChEMBL-Cells; CHEMBL3308667
DR   ChEMBL-Targets; CHEMBL614826
DR   Cosmic; 688044
DR   Cosmic; 874383
DR   Cosmic; 905203
DR   Cosmic; 907058
DR   Cosmic; 1007155
DR   Cosmic; 1477417
DR   Cosmic; 2230117
DR   Cosmic-CLP; 907058
DR   DepMap; ACH-002040
DR   ECACC; 92042701
DR   EGA; EGAS00001000978
DR   GDSC; 907058
DR   GEO; GSM827367
DR   GEO; GSM1669886
DR   IARC_TP53; 21375
DR   LINCS_LDP; LCL-1285
DR   PharmacoDB; HMVII_555_2019
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_1282
DR   PubChem_Cell_line; CVCL_1282
DR   RCB; RCB0777
DR   RCB; RCB3685
DR   TKG; TKG 0318
DR   Wikidata; Q54889975
RX   CelloPub=CLPUB00585;
RX   PubMed=2166075;
RX   PubMed=3361142;
RX   PubMed=15467732;
RX   PubMed=12068308;
RX   PubMed=20164919;
RX   PubMed=20215515;
RX   PubMed=25877200;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Japanese.
CC   Characteristics: Pigmented.
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly469Val (c.1406G>T); ClinVar=VCV000044803; Zygosity=Heterozygous (Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (PubMed=12068308; PubMed=15467732; Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Asn268Ile (c.803A>T); Zygosity=Heterozygous (Cosmic-CLP; DepMap).
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Genome ancestry: African=0.4%; Native American=0%; East Asian, North=76.31%; East Asian, South=21.9%; South Asian=0.25%; European, North=0.78%; European, South=0.36% (PubMed=30894373).
CC   Derived from site: In situ; Vagina; UBERON=UBERON_0000996.
ST   Source(s): Cosmic-CLP; ECACC; PubMed=25877200; RCB; TKG
ST   Amelogenin: X
ST   CSF1PO: 13
ST   D13S317: 11
ST   D16S539: 11
ST   D18S51: 15
ST   D21S11: 29
ST   D3S1358: 14,15
ST   D5S818: 12
ST   D7S820: 8,14
ST   D8S1179: 10
ST   FGA: 23
ST   Penta D: 11
ST   Penta E: 5,21
ST   TH01: 6,9
ST   TPOX: 8
ST   vWA: 16,17
DI   NCIt; C27394; Vaginal melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   65Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 39
//
RX   CelloPub=CLPUB00585;
RA   Kasuga T., Nojiri I., Furuse K., Kubo E., Noda Y., Sugano H.,
RA   Sakamoto G.;
RT   "Establishment of human melanoma cell like (HMV-II).";
RL   (In) Proceedings of the Japanese Cancer Association 35th annual meeting; pp.102-102; Tokyo (1976).
//
RX   PubMed=2166075; DOI=10.1128/jcm.28.6.1147-1150.1990;
RA   Moriuchi H., Oshima T., Nishimura H., Nakamura K., Katsushima N.,
RA   Numazaki Y.;
RT   "Human malignant melanoma cell line (HMV-II) for isolation of
RT   influenza C and parainfluenza viruses.";
RL   J. Clin. Microbiol. 28:1147-1150(1990).
//
RX   PubMed=3361142; DOI=10.1111/1523-1747.ep12560926;
RA   Nakamura T., Seki S., Matsubara O., Ito S., Kasuga T.;
RT   "Specific incorporation of 4-S-cysteinylphenol into human melanoma
RT   cells.";
RL   J. Invest. Dermatol. 90:725-728(1988).
//
RX   PubMed=15467732; DOI=10.1038/sj.onc.1208152;
RA   Tanami H., Imoto I., Hirasawa A., Yuki Y., Sonoda I., Inoue J.,
RA   Yasui K., Misawa-Furihata A., Kawakami Y., Inazawa J.;
RT   "Involvement of overexpressed wild-type BRAF in the growth of
RT   malignant melanoma cell lines.";
RL   Oncogene 23:8796-8804(2004).
//
RX   PubMed=12068308; DOI=10.1038/nature00766;
RA   Davies H., Bignell G.R., Cox C., Stephens P.J., Edkins S., Clegg S.,
RA   Teague J.W., Woffendin H., Garnett M.J., Bottomley W., Davis N.,
RA   Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J.,
RA   Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S.,
RA   Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C.S.,
RA   Shipley J.M., Hargrave D., Pritchard-Jones K., Maitland N.J.,
RA   Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A.,
RA   Flanagan A.M., Nicholson A., Ho J.W.C., Leung S.Y., Yuen S.T.,
RA   Weber B.L., Seigler H.F., Darrow T.L., Paterson H.F., Marais R.,
RA   Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.;
RT   "Mutations of the BRAF gene in human cancer.";
RL   Nature 417:949-954(2002).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//